GSE122922
AR-V7 targets the oncogenic genes in castration resistant prostate cancer. [ChIP]
To elucidate the AR-V7 role, we performed ChIP-seq on H3K4me1, H3K4me3, H3K27ac, and AR antibody recognizing the N-terminus of AR and AR splice variants (AR-Vs) using LNCaP and LNCaP95 cells. We showed  399 AR-V7 targeted regions in LNCaP95, most of the AR-V7 target regions could be commonly activated by hormone stimulated AR. However, 22 regions were identified as AR-V7 specific regions. In addition, we show here that AR-V7 can transcript in the ligand independent manner in LNCaP95, unlike LNCaP.  We identified the AR-V7 target gene contributing to the CRPC progression. Overall design: 1) Examination of AR and AR-V7 target regions and 2 different histone modifications in LNCaP or LNCaP95 cells. 2) Examination of  different histone modifications in shRNA-mediated knockdown LNCaP95 cells.